Advertisement

Advertisement

News

SABCS 2023: Can Pembrolizumab Plus Olaparib Improve Survival in Advanced Triple-Negative Breast Cancer?

News

SABCS 2023: Combination of Two HER2-Targeted Agents in Advanced HER2-Positive Breast Cancer

News

Daratumumab-Based Regimen for Lenalidomide-Refractory Myeloma: An Italian Perspective

News

Vedotin Antibody-Drug Conjugate: Focus of First-in-Human Study in Advanced Solid Tumors

News

ESMO 2023: Phase III Trial Assesses Chemoimmunotherapy Regimen in Urothelial Carcinoma

Medical Literature

Can a Novel Scoring System Predict Outcomes With CAR T-Cell Therapy for Myeloma?

Medical Literature

Biological Mechanisms Behind Immune Checkpoint Inhibitors in Bladder Cancer

Melinda L. Telli, MD, on Choosing Among Many Treatment Options for HER2-Positive Breast Cancer

Alexander N. Shoushtari, MD, on Dosing Nivolumab

View More

Advertisement

JNCCN Spotlights

(UPDATE) Pembrolizumab (NSCLC)

View More

More

News

More MagnetisMM-3 Results Support Elranatamab’s Potential in Myeloma

Comparing Triplet Regimens in Newly Diagnosed Myeloma: Is There a Clear Winner?

EV-103 Update on Preoperative Immunotherapy for Muscle-Invasive Bladder Cancer

ESMO 2023: Focus on Pathologic Complete Response in KEYNOTE-756 Breast Cancer Trial

ESMO 2023: Phase III Trial Assesses Chemoimmunotherapy Regimen in Urothelial Carcinoma

Final Phase III Trial Results of Trastuzumab Duocarmazine in Metastatic Breast Cancer

ESMO 2023: Triplet Immunotherapy Regimen Under Study in Advanced Liver Cancer

Update on Use of Dato-DXd Plus Durvalumab in Triple-Negative Breast Cancer

View More

Advertisement

Published

Medical Literature

Daratumumab Combination Therapy for Relapsed or Refractory Multiple Myeloma

Ixazomib Plus Lenalidomide/Dexamethasone in Relapsed or Refractory Myeloma: China Continuation Study

Combination Treatment With or Without Transplantation in Multiple Myeloma

Impact of Subsidies on Use of Immunomodulatory Drugs in Medicare Beneficiaries With Myeloma

View More

Ongoing

CE Activities

Similarities and Differences in the Efficacy of Neoadjuvant and Adjuvant Immunotherapies for Localized NSCLC

Changing Treatment Landscape of Metastatic Head and Neck Squamous Cell Carcinoma With Anti–PD-1/PD-L1 Agents

Tumor Mutational Burden, Neoantigens, and a Pathway to Predicting Response to Checkpoint Inhibitors

Minimizing the Impact of imAEs and Maximizing Efficacy of ICIs: AEs Affecting the Skin

View More

Available

Clinical Trials

A Study to Learn About the Effects of the Combination of Elranatamab

A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis

Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced NSCLC

A Phase III, Randomized, Placebo-Controlled Clinical Study of SBRT With or Without Pembrolizumab in Participants With Medically Inoperable NSCLC (KEYNOTE-867)

View More

Resources

For Your Patients

ONS Immunotherapy News

ONS Immunotherapy Community

Society for Immunotherapy of Cancer Patient Resources

CancerCare on Immunotherapy

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2023 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.